Mankind Pharma share news, announcements and annual reports
NSE: MANKINDBSE: 543904Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,469.30.
30 Oct: open ₹2,469.30, high ₹2,528.00, low ₹2,467.40
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,02,964 Cr119th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 45.79
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.86
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.30
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,81,49752.0% delivered
Mankind Pharma has 312 announcements on record, routine notices left out; 10 in the 30 days to 31 Oct 2026, the latest on 29 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Mankind Pharma quarterly results
The board met on 26 Oct 2026 to consider financial results
Notice filed 8 Oct 2026
To consider and approve the financial results for the period ended September 30, 2026
Mankind Pharma annual reports, presentations and earnings calls
The company's own documents, latest first.Mankind Pharma financials, year by year
Annual reports4
- Annual report, year to Mar 20269 Jul 2026
- Annual report, year to Mar 202515 Jul 2025
- Annual report, year to Mar 202418 Jul 2024
- Annual report, year to Mar 202328 Aug 2023, a zip file
Investor presentations19
- Investor Presentation27 Oct 2026
- Investor Presentation26 Oct 2026
- Investor Presentation26 Oct 2026
- Investor Presentation30 Jul 2026
- Investor Presentation19 May 2026
14 earlier presentations
- Investor Presentation3 Feb 2026
- Investor Presentation6 Nov 2025
- Investor Presentation31 Jul 2025
- Investor Presentation21 May 2025
- Investor Presentation23 Jan 2025
- Investor Presentation5 Nov 2024
- Investor Presentation31 Jul 2024
- Investor Presentation25 Jul 2024
- Investor Presentation15 May 2024
- Investor Presentation31 Jan 2024
- Presentation at 42nd Annual JP Morgan Healthcare Conference10 Jan 2024
- Investor Presentation31 Oct 2023
- Investor Presentation2 Aug 2023
- Investor Presentation30 May 2023
Earnings calls31
- Transcript30 Oct 2026
- Link of Recording26 Oct 2026
- Transcript4 Aug 2026
- Link of Recording30 Jul 2026
- Transcript26 May 2026
26 earlier call documents
- Link of Recording20 May 2026
- Transcript9 Feb 2026
- Link of Recording3 Feb 2026
- Transcript11 Nov 2025
- Link of Recording6 Nov 2025
- Transcript6 Aug 2025
- Link of Recording1 Aug 2025
- Transcript27 May 2025
- Link of Recording21 May 2025
- Transcript30 Jan 2025
- Investor Conference Call for Q3 & 9M FY25 Audio Recording24 Jan 2025
- Investor Conference Call for Q2 & H1FY25 Transcript11 Nov 2024
- Link of Recording5 Nov 2024
- Investor Conference Call for Q1FY25 Transcript6 Aug 2024
- Transcript of Conference Call held on July 26, 2024 in relation to acquisition of 100% stake in Bharat Serums and Vaccines Limited2 Aug 2024
- Investor Conference Call for Q1FY25 Audio Recording31 Jul 2024
- Link of Recording27 Jul 2024
- Investor Conference Call for Q4FY24 Transcript22 May 2024
- Investor Conference Call for Q4FY24 Audio Recording16 May 2024
- Investor Conference Call for Q3 FY24 Transcript7 Feb 2024
- Investor Conference Call for Q3 FY24 Audio Recording2 Feb 2024
- Transcript7 Nov 2023
- Investor Conference Call for Q2FY24 Audio Recording1 Nov 2023
- Link of Recording3 Aug 2023
- Performance and Business Update Call for Q4FY23 & FY23 Transcript6 Jun 2023
- Link of Recording31 May 2023
Mankind Pharma merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Mankind Pharma share news and announcements
Newest first. Page 1 of 7.
Oct 2026
29 Oct · Rating
26 Oct · Results
22 Oct · Analysts
22 Oct · Analysts
15 Oct
15 Oct · Board meeting
12 Oct · Analysts
Sep 2026
28 Sep · Management
28 Sep · General Updates
15 Sep · General Updates
11 Sep · Analysts
7 Sep · General Updates
1 Sep · Disclosure
Aug 2026
31 Aug
22 Aug
18 Aug · Meeting
13 Aug · Business
10 Aug · Board meeting
10 Aug · Analysts
Jul 2026
30 Jul · Results
27 Jul · General Updates
17 Jul · Analysts
16 Jul · Board meeting
11 Jul · Board meeting
Jun 2026
30 Jun
15 Jun · Analysts
2 Jun · Business
May 2026
27 May · Analysts
20 May · Analysts
19 May · Management
19 May · Disclosure
19 May · Results
12 May · Rating
8 May · Analysts
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 30 Oct 2026Credit ratingup 0.95%+1.2 pts vs Nifty 500market median 0.0% · volume 0.9× usual · delivery −2.6 pts against usual · The announcement
- 26 Oct 2026Resultsup 4.49%+3.6 pts vs Nifty 500market median −0.7% · five sessions +12.7% (+10.5 pts vs Nifty 500) · volume 1.7× usual · delivery −11.3 pts against usual · The announcement
- 29 Sep 2026Board or managers changedup 4.49%+5.1 pts vs Nifty 500market median 0.0% · five sessions +2.6% (+2.8 pts vs Nifty 500) · volume 4.8× usual · delivery −21.6 pts against usual · The announcement
- 31 Aug 2026Board or managers changedup 1.52%+1.9 pts vs Nifty 500market median 0.0% · five sessions −2.3% (−1.1 pts vs Nifty 500) · volume 1.1× usual · delivery +13.1 pts against usual · The announcement
- 30 Jul 2026Resultsdown 0.65%−0.7 pts vs Nifty 500market median −0.7% · five sessions −6.1% (−7.7 pts vs Nifty 500) · volume 0.8× usual · delivery −8.4 pts against usual · The announcement
- 20 May 2026Resultsup 3.66%+3.4 pts vs Nifty 500market median −0.7% · five sessions −2.8% (−4.4 pts vs Nifty 500) · volume 7.5× usual · delivery −22.0 pts against usual · The announcement
- 20 May 2026Board or managers changedup 3.66%+3.4 pts vs Nifty 500market median 0.0% · five sessions −2.8% (−4.4 pts vs Nifty 500) · volume 7.5× usual · delivery −22.0 pts against usual · The announcement
- 13 May 2026Credit ratingup 1.21%+0.9 pts vs Nifty 500market median 0.0% · five sessions +4.8% (+3.8 pts vs Nifty 500) · volume 1.1× usual · delivery −14.5 pts against usual · The announcement
- 23 Apr 2026Credit ratingup 2.59%+3.4 pts vs Nifty 500market median 0.0% · five sessions +1.0% (+1.5 pts vs Nifty 500) · volume 1.8× usual · delivery −13.0 pts against usual · The announcement
- 25 Feb 2026Credit ratingup 4.92%+4.5 pts vs Nifty 500market median 0.0% · five sessions +7.4% (+11.3 pts vs Nifty 500) · volume 2.3× usual · delivery −2.1 pts against usual · The announcement
20 earlier announcements
- 4 Feb 2026Resultsdown 3.39%−3.8 pts vs Nifty 500market median −0.7% · five sessions −4.1% (−5.4 pts vs Nifty 500) · volume 2.3× usual · delivery −17.7 pts against usual · The announcement
- 19 Jan 2026Credit ratingdown 2.68%−2.2 pts vs Nifty 500market median 0.0% · five sessions −3.1% (+0.2 pts vs Nifty 500) · volume 0.9× usual · delivery −10.2 pts against usual · The announcement
- 14 Nov 2025Credit ratingup 0.45%+0.4 pts vs Nifty 500market median 0.0% · five sessions −0.8% (−1.4 pts vs Nifty 500) · volume 1.3× usual · delivery +11.6 pts against usual · The announcement
- 7 Nov 2025Resultsdown 2.05%−2.1 pts vs Nifty 500market median −0.7% · five sessions −2.3% (−3.5 pts vs Nifty 500) · volume 3.0× usual · delivery −4.1 pts against usual · The announcement
- 30 Oct 2025Credit ratingup 0.12%+0.6 pts vs Nifty 500market median 0.0% · five sessions −5.5% (−3.7 pts vs Nifty 500) · volume 0.9× usual · delivery −6.1 pts against usual · The announcement
- 11 Aug 2025Board or managers changeddown 1.20%−2.0 pts vs Nifty 500market median 0.0% · five sessions +0.2% (−2.0 pts vs Nifty 500) · volume 0.6× usual · delivery +5.2 pts against usual · The announcement
- 1 Aug 2025Dividenddown 0.04%+1.0 pts vs Nifty 500market median 0.0% · five sessions −1.1% (−0.2 pts vs Nifty 500) · volume 0.7× usual · delivery −20.7 pts against usual · The announcement
- 26 Mar 2025Credit ratingup 0.24%+1.0 pts vs Nifty 500market median 0.0% · five sessions +1.0% (+1.8 pts vs Nifty 500) · volume 0.4× usual · delivery −10.8 pts against usual · The announcement
- 27 Feb 2025Credit ratingdown 2.05%−1.5 pts vs Nifty 500market median 0.0% · five sessions −2.3% (−1.5 pts vs Nifty 500) · volume 0.9× usual · delivery +8.6 pts against usual · The announcement
- 6 Nov 2024Resultsup 1.27%−0.3 pts vs Nifty 500market median −0.7% · five sessions −3.4% (−1.9 pts vs Nifty 500) · volume 6.6× usual · delivery −25.0 pts against usual · The announcement
- 6 Nov 2024Board or managers changedup 1.27%−0.3 pts vs Nifty 500market median 0.0% · five sessions −3.4% (−1.9 pts vs Nifty 500) · volume 6.6× usual · delivery −25.0 pts against usual · The announcement
- 6 Nov 2024Credit ratingup 1.27%−0.3 pts vs Nifty 500market median 0.0% · five sessions −3.4% (−1.9 pts vs Nifty 500) · volume 6.6× usual · delivery −25.0 pts against usual · The announcement
- 1 Oct 2024Credit ratingup 2.31%+2.2 pts vs Nifty 500market median 0.0% · five sessions +3.3% (+6.3 pts vs Nifty 500) · volume 0.7× usual · delivery −12.6 pts against usual · The announcement
- 30 Sep 2024Credit ratingdown 2.75%−1.8 pts vs Nifty 500market median 0.0% · five sessions −1.2% (+4.2 pts vs Nifty 500) · volume 1.0× usual · delivery +7.5 pts against usual · The announcement
- 7 Aug 2024Credit ratingup 1.32%−0.5 pts vs Nifty 500market median 0.0% · five sessions +7.1% (+5.9 pts vs Nifty 500) · volume 0.6× usual · delivery +8.4 pts against usual · The announcement
- 10 Jul 2024Credit ratingup 2.27%+2.7 pts vs Nifty 500market median 0.0% · five sessions +0.6% (0.0 pts vs Nifty 500) · volume 4.3× usual · delivery −13.2 pts against usual · The announcement
- 16 May 2024Resultsdown 4.48%−5.4 pts vs Nifty 500market median −0.7% · five sessions −3.8% (−6.2 pts vs Nifty 500) · volume 8.4× usual · delivery −13.9 pts against usual · The announcement
- 26 Apr 2024Credit ratingdown 1.23%−1.1 pts vs Nifty 500market median 0.0% · five sessions −3.5% (−3.9 pts vs Nifty 500) · volume 0.2× usual · delivery +1.0 pts against usual · The announcement
- 1 Feb 2024Resultsup 2.32%+2.4 pts vs Nifty 500market median −0.7% · five sessions +6.4% (+4.9 pts vs Nifty 500) · volume 3.1× usual · delivery +0.4 pts against usual · The announcement
- 1 Nov 2023Resultsup 0.12%+0.5 pts vs Nifty 500market median −0.7% · five sessions +3.0% (+0.7 pts vs Nifty 500) · volume 2.3× usual · delivery +5.8 pts against usual · The announcement
Mankind Pharma results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.